Allogeneic SCT is curative for bone marrow failure in Fanconi anemia (FA) patients but the optimal conditioning regimen is undetermined. We report here our experience with 56 FA patients who underwent allogeneic matched related SCT. The conditioning regimen varied according to time of SCT and disease status at SCT; 22 patients (group A) received Cy 20 mg/kg, thoracoabdominal radiation and antithymocyte globulins (ATG); and 34 patients (group B) received Cy 60 mg/kg and ATG. Median time to engraftment was similar (14 days) in both groups. Hemorrhagic cystitis was significantly more common in group B. Overall survival and event-free survival of all patients were 85 and 78.3% respectively. For groups A and B respectively, overall survival was 72.5 and 96.9% (P ¼ 0.013); and event-free survival was 72.5 and 82.3% (P ¼ 0.3). The use of the nonradiation Cy/ATG regimen in matched related SCT for FA patients offers better overall and event-free survival.
Introduction
Fanconi anemia (FA) is an autosomal recessive disorder characterized by congenital malformations, progressive marrow failure, and a predisposition to acute myelogenous leukemia and solid tumors. [1] [2] [3] [4] [5] For bone marrow failure, it has been universally accepted and proven that allogeneic SCT is the therapy of choice, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] but the optimal conditioning regimen remains undetermined.
We provide here an update of our experience at King Faisal Specialist Hospital and Research Center (KFSHRC) in the form of a retrospective comparison between two conditioning regimens (with and without radiation) in a large cohort of patients, all treated at the same institution.
Patients and methods
From April 1995 through December of 2005, 56 patients with Fanconi Anemia underwent allogeneic SCT at KFSHRC; the diagnosis was confirmed by chromosomal breakage studies with mitomycin-C and/or Diepoxybutane. The median age at the time of SCT was 7.6 years (range, 2.5-14.6 years). All patients underwent bone marrow examination, both morphologic and cytogenetic, prior to SCT to check for evidence of myelodysplasia or leukemia. Starting in January 2003, if the HLA typing of the family members did not reveal a suitable matched donor, then a suitable matched unrelated cord blood unit was sought; those patients however are not included in this analysis, nor are the patients who had evidence of myelodysplasia, clonal abnormality, and/or leukemia prior to SCT.
Conditioning regimen
From April 1995 through March 1999, 22 patients (group A) received Cy i.v. at a total dose of 20 mg/kg plus thoracoabdominal irradiation (TAI) at a dose of 400 cGy in addition to equine antithymocyte globulins (ATG) at a dose of 40 mg/kg i.v. given on days À5, À4, À3 and À2. And from April 1999 through December 2005, 34 patients (group B) received Cy i.v. at 60 mg/kg plus equine ATG at a dose of 40 mg/kg i.v. given on days À5, À4, À3 and À2; no radiation therapy was given. Mesna was administered to all patients during the conditioning regimen to prevent hemorrhagic cystitis. Patients who developed allergic reactions to the equine product received rabbit ATG at 13 mg/kg on the same days; the rabbit product was well tolerated and continued for all patients who received it.
Donors
All 56 patients received their SCT from matched related donors (six out of six antigen match; HLA-A, and HLA-B were analyzed by serology and HLA-DR by high resolution); all donors had documented negative chromosomal breakage studies. Harvested marrows were not manipulated. The median CD34-positive cell count per kg recipient body weight for the groups A and B, respectively, was 5.6 Â 10 6 /kg, and 6.3 Â 10 6 /kg.
GVHD prophylaxis
In both groups, GVHD prophylaxis was with CSA at the standard doses plus equine ATG at 20 mg/kg i.v. on days þ 2, þ 4, þ 6, þ 8, þ 10, and þ 12; CSA was tapered and discontinued by 6 months after SCT unless the patient had GVHD. Patients who developed allergic reactions to the equine product received rabbit ATG at 7 mg/kg on the same days. Early on, seven patients in group A received MTX at 10 mg/m 2 on days þ 1, þ 3, and þ 6. This practice was abandoned later due to the excessive mucositis that these patients suffered from.
Supportive care
All patients were treated in HEPA-filtered rooms and were isolated until engraftment; engraftment was defined as an ANC of 500 Â 10 6 /l for 3 consecutive days. All patients received i.v. immunoglobulins (IVIG) every 2 weeks at a dose of 500 mg/kg from day À4 until day þ 90 as well as acyclovir 45 mg/kg/day from day À3 to day þ 28. Starting June 1998, all patients received fluconazole therapy from day 0 until engraftment. No prophylactic ganciclovir was given, and CMV was monitored by weekly antigenemia tests. All blood products were leukocyte filtered and irradiated. G-CSF was given to 14 patients in group A (63.6%), and to 26 patients in group B (76.5%).
Results

Engraftment
All patients had initial engraftment; for groups A and B respectively, the median time to engraftment was 14 days (range, 11-32 days), and 14 days (range, 9-31 days). The median time to a self-sustained platelet count of 20 Â 10 9 /l for the groups A and B respectively was 39 days (range, 18-64 days), and 30 days (range, 17-139 days). Chimerism was documented by different methodologies; for patients presenting before 2000, it was documented using variable nontandem repeats analysis for same-sex transplants and with FISH for opposite-sex transplants, and after 2000, chimerism was documented using the short tandem repeats method (Table 1) .
Graft vs host disease
Acute and chronic GVHD were defined according to established criteria. 16 The incidence of GVHD was comparable in groups A and B; acute GVHD, grade 2 or higher, occurred in two patients (9%) in group A and in three patients (9%) in group B (P ¼ 0.96), two patients in each of group A and group B had limited chronic GVHD. Seven patients in group A received MTX; none of them developed acute GVHD, whereas two of the remaining 15 in group A developed grade II aGVHD (P ¼ 0.33).
Regimen-related toxicities
Patients in both groups developed mucositis, requiring analgesia; no differences were noted in the incidence and severity of mucositis. Veno-occlusive disease (VOD) liver developed in two patients in group A and in three patients in group B (P ¼ 0.97). The use of a higher dose of Cy was associated with a strikingly higher incidence of hemorrhagic cystitis (HC); one patient in group A vs eight patients in group B, the difference reaching statistical significance of P ¼ 0.04. Two cases of malignancy were observed in group A; one patient had squamous cell carcinoma of the tongue that developed 5 years post SCT, he had partial glossectomy and is now alive and well with no evidence of disease 10 years post SCT, and another patient developed acute myeloid leukemia 28 months post SCT after delayed graft loss, she subsequently died due to sepsis. No malignancy has thus far been noted in group B (Table 2) .
Survival estimates
The overall and event-free survival rates for all the 56 patients are 85 and 78.3% respectively (Figures 1 and 2) . For groups A and B respectively, the overall survival rate (Figure 3 ) was 72.5 and 96.9% (P ¼ 0.013) and the eventfree survival rate (Figure 4 ) was 72.5 and 82.3% (P ¼ 0.3); the event was defined as death or graft failure, whichever occurred first.
Follow-up and causes of death
Sixteen of the patients in group A are alive with no evidence of disease at a median follow-up of 81.5 months (range, 1.7-115 months). Among the six patients who died, two had delayed graft failure 16 months and 28 months post SCT; the graft failure was defined as hypoplasia of the bone marrow and complete disappearance of donor cells on chimerism analysis, the CD34 for the two patients was 1.7 Â 10 6 /kg and 6.3 Â 10 6 /kg, both were off CSA when the graft failure occurred and both succumbed to sepsis. Three patients died from complications in the first 100 days post SCT (two died of CMV infection and one had an intracranial hemorrhage); the sixth patient died from sepsis reportedly in a local hospital 14 months post SCT despite engraftment.
In group B, 33 patients remain alive with no evidence of disease at a median follow-up of 33.7 months (range, 1.1-82.6 months); only one death occurred after engraftment. The patient developed sepsis and succumbed to ARDS five months post SCT. There were, however, four partial delayed graft failures (defined as hypoplasia of the bone marrow with persistence of 5% or more donor cells on chimerism analysis); one patient had good initial engraftment in all three lines and then developed gradual decline in her counts requiring support with blood products despite continued mixed chimerism. Her bone marrow showed marked hypoplasia; she was retransplanted 2.5 years after the first SCT, using Cy/TAI and is now fully engrafted and well 14 months after the second SCT. The other three patients had engrafted their white cells but never attained independence from blood product transfusions. All three had documented mixed chimerism; one was able to recover his counts when started back on CSA, the other two required a boost infusion of bone marrow 9 and 10 months respectively. Later, after preparation with ATG only, both now enjoy normal counts, with continued mixed chimerism.
Discussion
Allogeneic SCT can be curative for bone marrow failure in patients with FA, but the rarity of this illness has hampered the launch of large prospective randomized studies to identify a conditioning regimen that would be suitable for the different stages of the illness (hypoplasia, myelodysplasia, leukemia), with the minimum possible side effects. However, to avoid severe toxicity in these patients, it is generally accepted that low doses of chemotherapy and radiation should be used in the conditioning of such patients. 6, 17, 18 This approach was pioneered by Socie´et al.
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when they used Cy at 20 mg/kg i.v. in addition to 500 cGy of TAI. With this regimen, the survival at 54 months and at 100 months was 74.4 and 58.8% respectively, with a median follow-up of more than 72 months. With the exception of a high incidence of GVHD, acute and chronic, this protocol was fairly well tolerated; HC and VOD of the liver developed in 8 and 2% of the patients respectively. Adding ATG to the pre-transplant conditioning was reported to be associated with increased survival in FA patients. Kohli-Kumar et al. 19 reported 18 FA patients who were conditioned with Cy 20 mg/kg, and TAI plus ATG. There was one delayed graft failure, no cases of acute GVHD and three cases of chronic GVHD; oral mucositis was the only significant complication. We previously reported similar results in 19 patients using the same regimen, 20 three additional patients have since been transplanted in the same way; 16 of the total 22 patients are now alive and free of disease (group A).
The use of radiation is a major risk factor for posttransplant malignancies in patients with aplastic anemia undergoing allogeneic SCT. [21] [22] [23] Many investigators have therefore recently opted for radiation-free protocols in FA patients. At our institution, we launched a protocol in 2000 using Cy at 60 mg/kg plus ATG (group B); early results on the first 22 of the 34 patients reported here have been published. 14 In this paper, we provide an update and a comparison between the two regimens; one salient conclusion is that the radiation therapy arm (group A) had a significantly inferior overall survival when compared to the nonradiation arm. Another important finding is that the use of higher doses of Cy in group B led to a significantly higher incidence of hemorrhagic cystitis. Others also used the nonradiation approach; Zanis-Neto et al.
11 recently reported their experience comparing Cy 80 mg/kg with Cy 60 mg/kg; all seven patients given Cy 80 mg/kg and 21 of the 23 patients given Cy 60 mg/kg were alive at a median of 47 months and 16 months respectively; no ATG was used in this study. It is noteworthy that only one patient developed hemorrhagic cystitis, an incidence significantly lower than that reported in our Saudi patients despite the use of the same dose of Cy, which underscores the impact of the underlying genetic defect on the eventual outcome.
In conclusion, the use of radiation therapy does not appear necessary in the preparation of FA patients for allogeneic SCT; it furthermore seems to be associated with an inferior overall survival. The dose of Cy 60 mg/kg appears to be adequate to ensure engraftment with and without ATG but smaller doses of Cy may be as effective, particularly when used in combination with agents such as fludarabine. Tan et al. 24 reported recently excellent results in 11 FA patients after conditioning with Cy 20 mg/kg, fludarabine 175 mg/m 2 and ATG 150 mg/kg. In addition, we suggest that the use of ATG post SCT may offer protection against GVHD in this population.
